Canopy sponsors clinical trial for mental-health disorder

First of its kind in North America, and possibly the world

The first substantial clinical trial to examine the effects of CBD in Social Anxiety Disorder (SAD) is expected to commence in January 2020 at McMaster University in Ontario, Canada.

The randomized placebo-controlled study of approximately 160 adults with SAD will be the first of its kind in North America, and possibly the world.

CANOPY CBD OIL

The robust phase-two study will evaluate the efficacy, therapeutic effects, safety and tolerability of a Canopy CBD-oil product called CHI-902.

It will also examine the effects of the CBD oil on the human endocannabinoid system.

It will also examine the effects of the CBD oil on the human endocannabinoid system.

THE BLISS MOLECULE

Anandamide and 2-AG are naturally occurring cannabinoids in the body. Anandamide was dubbed “the bliss molecule” by scientists who discovered it.

The clinical trial will evaluate how CHI-902 affects the levels of these two important endocannabinoids in study participants, before and after treatment.

The study will be led by Dr. Mark Ware, Canopy Health Innovations.